Latest news with #cancerDrug
New York Times
02-07-2025
- Health
- New York Times
Robert Holton Dies at 81; His Potent Chemo Drug Saved Lives — and Trees
Robert A. Holton, a chemist who created a cheaper and environmentally kinder way to produce the cancer drug Taxol, synthesizing its key compound instead of extracting it from harvested yew trees, died on May 21 at his home in Tallahassee, Fla. He was 81. His death was confirmed by his son Paul Holton who said the cause was emphysema. In 1993, in his laboratory at Florida State University, where he was a professor, Dr. Holton created a method to produce Taxol. He constructed the drug, molecule by molecule, mimicking the plant's chemistry and eliminating the need to source material from the endangered western yew tree, Taxus brevifolia. He called the technique, which produced the medication in high amounts, the metal alkoxide process. He licensed his methodology to Bristol Myers Squibb, which became the first pharmaceutical company to manufacture Taxol. Generic versions are sold under the name paclitaxel. 'There was a worldwide race underway to synthesize it,' Dr. Jeff Boyd, chief scientific officer for the Northwell Health Cancer Institute in Manhasset, N.Y., on Long Island, said in an interview. 'Many groups were working on it because what was needed was a cheap and readily obtainable source of the drug. He was the first to achieve total organic synthesis.' Dr. Holton completed the artificially made compound on Dec. 9, 1993, beating dozens of competitors. Although scientists at the Scripps Research Institute in La Jolla, Calif., announced that they had also succeeded in synthesizing the drug, Dr. Holton's team was the first to publish details of its methods in a scientific journal. Before Dr. Holton's achievement, not only did three yews per patient have to die — because the bark where the anticancer alkaloid was first isolated had to be fully stripped — but the forests where they grew also stood to lose the bulk of these conifers. Want all of The Times? Subscribe.
Reuters
24-06-2025
- Business
- Reuters
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
June 24 (Reuters) - Royalty Pharma (RPRX.O), opens new tab said on Tuesday will pay up to $2 billion to Revolution Medicines (RVMD.O), opens new tab to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
